Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Carl Sailer acquired 5,161 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was purchased at an average price of $4.84 per share, for a total transaction of $24,979.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Shares of NASDAQ:ACXP traded up $0.15 during midday trading on Thursday, hitting $4.81. The company had a trading volume of 14,945 shares, compared to its average volume of 220,100. Acurx Pharmaceuticals, Inc. has a 12 month low of $3.71 and a 12 month high of $8.74. The business has a fifty day moving average of $4.91.
Large investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Acurx Pharmaceuticals in the 3rd quarter worth $33,000. Tocqueville Asset Management L.P. bought a new position in shares of Acurx Pharmaceuticals in the 2nd quarter worth $64,000. Finally, Millennium Management LLC bought a new position in shares of Acurx Pharmaceuticals in the 3rd quarter worth $155,000. Institutional investors and hedge funds own 26.75% of the company’s stock.
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
Further Reading: Black Swan
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.